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Abstract
We analyzed CBCL/1½−5 Pervasive Developmental Problems (DSM-PDP) scores in 3- to 5-year-
olds from the Study to Explore Early Development (SEED), a multi-site case control study, with 
the objective to discriminate children with ASD (N = 656) from children with Developmental 
Delay (DD) (N = 646), children with Developmental Delay (DD) plus ASD features (DD-AF) (N 
= 284), and population controls (POP) (N = 827). ASD diagnosis was confirmed with the ADOS 
and ADI-R. With a cut-point of T ≥ 65, sensitivity was 80% for ASD, with specificity varying 
across groups: POP (0.93), DD-noAF (0.85), and DD-AF (0.50). One-way ANOVA yielded a large 
group effect (η2 = 0.50). Our results support the CBCL/1½−5’s as a time-efficient ASD screener 
for identifying preschoolers needing further evaluation.
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by 
impairments in social interaction/communication and restricted and repetitive behaviors 
(American Psychiatric Association 2013). Early identification of ASD is crucial because it 
facilitates early intervention, which is associated with better outcomes (Zwaigenbaum et al. 
2015) Because developmental conditions such as ASD may initially present in primary care 
settings, the American Academy of Pediatrics (AAP) published algorithms to help identify 
young children at risk for developmental disorders (Council on Children with Disabilities 
2006) and a diagnosis of ASD (Johnson et al. 2007). These algorithms include incorporating 
developmental and behavioral surveillance and screening with standardized tools into 
primary care visits. The ASD screening algorithm recommends screening with a 
standardized autism-specific tool at the 9-, 18- and 24-month visits for all children, 
regardless of risk status. The Modified Checklist for Autism in Toddlers (M-CHAT; Robins 
et al. 2001) has been widely used in preschool populations (under 3 years) to screen for ASD 
risk (Chlebowski et al. 2013; Robins et al. 2014; Pandey et al. 2008). In a 2014 sample of 
16,071 children (Robins et al. 2014), different cutoffs yielded widely different sensitivity 
(SENS) /positive predictive value (PPV) results (e.g., from 0.91/0.14 to 0.67/0.51), 
indicating a sharp trade-off between correct identifications and false positives.
The Child Behavior Checklist for Ages 1½−5 (CBCL/1½−5; Achenbach and Rescorla 2000) 
is a broad-spectrum assessment instrument. Its 99 items yield scores on seven empirically 
based syndromes (Emotionally Reactive, Anxious/Depressed, Somatic Complaints, 
Withdrawn, Sleep Problems, Attention Problems, and Aggressive Behavior), three broad-
spectrum scales (Externalizing, Internalizing, and Total Problems), and five DSM-oriented 
scales (Affective Problems, Anxiety Problems, Pervasive Developmental Problems (PDP), 
Attention Deficit/Hyperactivity problems, and Oppositional Defiant Problems). After 
publication of the DSM-5 (American Psychiatric Association 2013), the 2000 DSM-PDP 
scale (with 13 items) was renamed the DSM-Autism Spectrum Problems Scale and one of 
the 13 items was removed. However, we used the original 13-item DSM-PDP scale in the 
current study because the data were collected and scored before publication of the DSM-5.
Several studies have examined the performance of the CBCL/1½−5’s DSM-PDP scale and 
Withdrawn syndrome for ASD screening, usually using a T ≤ 65 cutoff (Rescorla 1988; 
Rescorla et al. 2015; Sikora et al. 2008; Muratori et al. 2011; Narzisi et al. 2013; Myers et al. 
2014). When differentiating children with ASD from typically developing children, the 
DSM-PDP scale’s SENS ranged from 80 to 97% and specificity (SPEC) ranged from 42 to 
91%. Using the Withdrawn syndrome to differentiate the ASD group from typically 
developing children, Muratori et al. (2011) reported SENS 89%, SPEC = 92%, and Rescorla 
et al. (2015) reported SENS = 78% and SPEC = 89%. When differentiating children with 
ASD from those with other psychiatric disorders, SENS was often unchanged but SPEC was 
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lower due to more false positives (e.g., PDP/Withdrawn: 55%/63% in Rescorla et al. 2015; 
60%/65% in; Muratori et al. 2011). These findings are consistent with other screeners that 
often do not differentiate autism well from other developmental disorders (Moody et al. 
2017). Using the Withdrawn syndrome, Havdahl et al. (2016) reported SENS = 0.63, SPEC 
= 0.65 when differentiating children with ASD from those with non-ASD developmental and 
behavioral/emotional problems, and Rescorla et al. (2015) reported SENS = 78% and SPEC 
= 53% when differentiating children with ASD from those with other developmental 
disabilities.
While earlier results are promising, the utility of the CBCL/1½−5 as an ASD screener needs 
testing in a large sample. The Study to Explore Early Development (SEED) (Schendel et al. 
2012) sample is ideal for this as (a) it is a multisite population-based case–control study, (b) 
children were classified with ASD after a comprehensive evaluation with gold standard 
instruments, and (c) CBCL scores for the large ASD group (n = 656) could be compared 
with those for three comparison groups children with developmental delays with some ASD 
features (DD-AF, n = 284); children with developmental delays without ASD features (DD-
noAF, n = 646); and children from a population sample (POP, n = 827). The overall goal of 
this study was to examine the utility of the CBCL/1½−5 as a screening tool for a diagnosis 
of ASD in preschool children. We hypothesized that mean DSM-PDP and Withdrawn scores 
would be rank-ordered ASD > DD-AF > DD > POP, with significant differences between all 
groups. Our primary hypothesis was that use of a T score ≥ 65 cutpoint on DSM-PDP and 
Withdrawn scores would discriminate the ASD group from the other three groups based on 
SENS, SPEC, positive predictive value (PPV), and negative predictive value (NPV), with 
false positive rates varying across the three comparison groups.
Methods
Participants
SEED was conducted in six sites (California, Colorado, Georgia, Maryland, North Carolina, 
and Pennsylvania), with the study protocol approved by Institutional Review Boards at each 
site. Parents provided signed consent for their child’s participation. Children eligible for this 
study were born between September 1, 2003 and August 31, 2006 (30–68 months of age), 
lived in one of the study catchment areas at birth and at the time of the first SEED study 
contact, and lived with a knowledgeable caregiver who could communicate in English (in 
California and Colorado, in English or Spanish). Children with a range of developmental 
disorders were identified from special education programs and healthcare providers in each 
site’s catchment area, including children with and without a previous ASD diagnosis. A 
population comparison group (POP) was ascertained through random sampling of birth 
certificates from state vital records. More details about the study design appear elsewhere 
(Wiggins et al. 2015a; DiGuiseppi et al. 2016).
Data Collection and Final Classification
For study enrollment and triage process, all SEED participants were administered the Social 
Communication Questionnaire (SCQ; Chandler et al. 2007) to screen for ASD symptoms. 
Several studies have shown that a SCQ cutoff of 11 maximized SENS and SPEC in young 
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children (Allen et al. 2007; Wiggins et al. 2007). Therefore, SEED defined a SCQ score of 
11 or above as an indicator of risk of ASD. Children with an SCQ lower than 11 and without 
a previous ASD diagnosis were given the Mullen Scales of Early Learning (MSEL; Mullen 
1995). Parents of children with MSEL scores < 78 completed the Vineland Adaptive 
Behavior Scales-Second Edition (Sparrow et al. 2005). Children with an SCQ score higher 
than 11 or with a previous ASD diagnosis received a comprehensive developmental 
evaluation consisting of the Autism Diagnostic Interview-Revised (ADI-R; de Bildt et al. 
2015) and the Autism Diagnostic Observation Schedule (ADOS; Le Couteur et al. 2008), the 
MSEL, and the Vineland-II. If SEED study clinicians suspected ASD, a comprehensive 
developmental evaluation was administered, even if the children had a SCQ score < 11 and 
no documented ASD diagnosis. As reported by Schendel et al. (2012), 34% of children who 
were assigned to receive an ASD clinical evaluation did not have a previous ASD diagnosis 
but were targeted for full assessment because of an SCQ score > 11 (32%) or because of 
clinical suspicion during the developmental evaluation (2%). The CBCL/1½−5 and Social 
Responsiveness Scale (SRS; Constantino et al. 2003; Constantino 2011) were administered 
to collect additional phenotypic information on enrolled children.
The SEED final classification was based on results of the ADI-R and the ADOS, taking the 
child’s overall developmental status into account. Children classified as ASD met ASD 
criteria on both the ADOS and ADI-R or met ASD criteria on the ADOS and one of three 
ADI-R criteria. Children who did not meet the ASD criteria were classified into the DD or 
POP groups (or an “Incomplete Classification” group, not included in our sample). Children 
in the DD group had received a developmental diagnosis (e.g., language delay, intellectual 
disability, or other delays) from a clinical provider, or received early intervention or special 
education services (Schendel et al. 2012). As noted above, the DD group was further divided 
into two subgroups (DD-AF and DD-noAF), with the DD-AF group more phenotypically 
similar than the DD-noAF group to the ASD group because of having some ASD features 
(Wiggins et al. 2015a, b).
As shown in Fig. 1 there were 3769 children enrolled in the SEED study. After excluding 
children who did not have sufficiently complete clinic visits to classify them as ASD or non-
ASD as well as children who had no CBCL/1½−5 scores, our sample comprised 2413 
children (64.0% of SEED sample). We used the same criteria for assignment to our four 
groups as Wiggins et al. (2015a), except that we eliminated children without CBCL/1½−5 
data, resulting in slightly smaller sample sizes in each group than those studied by Wiggins 
(e.g., ASD: n = 656 vs. 707, DD-AF: n = 284 vs. 305, DD-noAF: n = 646 vs. 690, and POP: 
n = 827 vs. 898).
Measures
We used several measures to assess developmental and behavioral characteristics of our four 
groups, namely the MSEL to assess developmental levels, the Vineland-II to assess adaptive 
functioning, and the SCQ, SRS, and ADOS to measure ASD characteristics.
Our primary measure was the CBCL/1½−5, a widely used instrument for identifying a range 
of behavioral and emotional problems among young children (Achenbach and Rescorla 
2000). Written at a 5th grade reading level, it contains 99 items, which the parent rates as 0 
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= Not True, as far as you know, 1 = Somewhat or Sometimes True, or 2 = Very True or 
Often True. As noted above, these 99 items are scored on seven statistically derived 
syndromes, five DSM-oriented scales, and three broad-spectrum scales. As in previous 
studies examining the CBCL/1½−5 as an ASD screener, we compared our groups on the 
DSM- PDP scale and the Withdrawn syndrome scale (see Table 1). For both scales, a 
normalized T score of ≥ 65 demarcates the clinical + borderline range (Achenbach and 
Rescorla 2000).
Data Analysis
Data were analyzed using the SAS System for Windows (Version 9.3; SAS Institute, Cary, 
NC). Maternal and child demographic covariates included maternal education, race/ 
ethnicity, poverty status, child age, and sex. Poverty status was determined using the U.S. 
Census Bureau 2015 Poverty Thresholds (United States Census Bureau 2015).
One-way analysis of variance (ANOVA) and Chi square tests were used to compare our four 
groups (ASD, DD-AF, DD-noAF, and POP) on demographic and behavioral/developmental 
characteristics. We used ANOVA to compare DSM-PDP and Withdrawn scores for our four 
groups, using an alpha level of p < 0.001 and effect sizes (η2) interpreted as small = 1 to 
5.9%, medium = 6 to 13.9%, and large ≥ 14% (Cohen 1988).
We next used receiver operating characteristics (ROC) analysis to obtain the area under the 
curve (AUC) statistic, which indicates how well the DSM-PDP and Withdrawn scales 
discriminated children in the ASD group from those in each of the other three groups. 
Because ROC output shows SENS and 1-SPEC values for a full range of cutpoints, one can 
decide which cutpoint appears “optimal” for each comparison group (i.e., the one that seems 
to maximize SENS while minimizing 1-SPEC).
In our primary analysis, we calculated decision statistics for both scales using the commonly 
used cutpoint of T ≥ 65, determining SENS, SPEC, PPV, and negative predictive value 
(NPV) when the ASD group was compared with each of the other three groups (DD-AF, 
DD-noAF, and POP).
Results
Group Differences in Demographic, Developmental, and Behavioral Characteristics
As seen in Table 2, the four groups did not differ by age, but the ASD group had the lowest 
percentage of girls and the POP group had the highest, with the two DD groups in between. 
The DD-AF group had the lowest percentage of children with white mothers, and the highest 
percentage of mothers who had not finished high school and families in poverty. The ASD 
group had the lowest scores on the MSEL, F (3, 2398) = 455.6, p < 0.001, η2 = 0.36, and the 
Vineland-II, F(3,1205) = 70.4, p < 0.001, η2 = 0.15. The ASD group had the highest scores 
on the SCQ, F(3,2396) = 1387.6, p < 0.001, η2 = 0.63, the SRS, F(3,162) = 58.8, p < 0.001, 
η2 = 0.52 (preschool), F(3,2130) = 1017.4, p < 0.001, η2 = 0.59 (child total), and the ADOS, 
F(1,854) = 1025.4, p < 0.001, η2 = 0.55. Student–Newman–Keuls (SNK) pair-wise 
comparisons indicated that all groups differed significantly from each other on all the 
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developmental and behavioral measures except for the SRS-preschool, on which the DD-
noAF and the POP groups did not differ from each other.
Group Differences in DSM‑PDP and Withdrawn Mean Scores
One-way ANOVAs yielded significant group effects for both DSM-PDP, F(3,2409) = 797.3, 
p < 0.001, η2 = 0.50, and Withdrawn, F(3,2409) = 662.2, p < 0.001, η2 = 0.45. SNK pair-
wise comparisons between groups were all significant, with the pattern ASD > DD-AF > 
DD-noAF > POP. For both scales, the differences between the ASD and DD-noAF and POP 
groups were ≥ 1.5 SD, whereas the difference between the ASD and DD-AF group was 
about 0.5 SD.
ROC Results
The “optimal” cutpoints derived from the ROC analysis and the AUCs for these cutpoints 
varied by both scale and comparison group, as shown by the AUCs and confidence intervals 
(CIs) in Table 3. AUCs for the DSM-PDP scale were 0.95 (95% CI 0.91–0.95) for ASD vs. 
POP, 0.90 (95% CI 0.88–0.91) for ASD vs. DD-noAF, and 0.71 (95% CI 0.67–0.75) for 
ASD vs. DD-AF. Results were very similar for the Withdrawn scale. The high AUCs and 
narrow CIs (i.e., span of only 0.03 points) indicate that both the PDP and Withdrawn scales 
discriminate very well between the ASD and the POP and DD-noAF groups. In contrast, the 
scales discriminate much less well between the ASD and DD-AF groups, as seen in the 
lower AUCs and wider CIs (i.e., span of 0.08 and 0.07 points). This is to be expected, given 
that the children in the DD-AF group, by definition, have ASD features.
Decision Statistics Results Using a T ≥ 65 Cutpoint
Our primary results involved calculation of decision statistics based on a cutpoint of T ≥ 65 
on the DSM-PDP scale or the Withdrawn syndrome. This is a commonly used cutpoint in 
previous ASD screening studies. Equivalent to the 93rd percentile, T ≥ 65 is widely used as 
a criterion for “deviance” for the CBCL/1½−5 on all narrow-band scales and syndromes, as 
it is the threshold for the “borderline” range. Table 3 shows decision statistics (i.e., SENS, 
SPEC, PPV, NPV) for T ≥ 65 when the ASD group was compared with each of the other 
three groups using the two scales. For DSM-PDP, SENS was 0.80 for all three comparisons, 
but SPEC varied across the POP, DD-noAF, and DD-AF comparison groups (0.93, 0.85, 
0.50), as did PPV (0.91, 0.85, 0.79) and NPV (0.86, 0.81, 0.52). The same pattern was found 
for Withdrawn, but SENS was much lower (0.66) whereas SPEC was somewhat higher 
(0.96, 0.91, 0.63). We also calculated decision statistics using the criterion of either DSM-
PDP or Withdrawn T ≥ 65, which differed only minimally from the results for only DSM-
PDP T ≥ 65, as shown in Table 3. This result is consistent with the fact that 97% of the 
children in the ASD group who scored T ≥ 65 on either scale had T ≥ 65 on the DSM-PDP 
scale, whereas only 80% of the children in the ASD group who scored T ≥ 65 on either scale 
had T ≥ 65 on the Withdrawn scale.
Discussion
Our results suggest that the DSM-PDP scale of the CBCL/1½−5 may be an effective means 
of identifying children with ASD features needing further evaluation. The CBCL/1½−5 is 
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more effective in distinguishing children with ASD from children with typical development 
and/or drawn from the POP controls or with DD but without ASD features than from 
children with DD and some ASD symptoms. Since we used a large population sample, state-
of-the-art evaluation procedures, and three comparison groups, our study represents a 
significant advance in testing the performance of the CBCL/1½−5 as an ASD screener.
Between-group differences on the DSM-PDP and Withdrawn scales yielded large effect 
sizes (η2 of 0.50 and 0.45), and all pairwise comparisons were significant. Mean score 
differences between the ASD group and the DD-noAF and POP groups were ≥ 1.5 SDs, 
whereas the difference between the ASD and DD-AF group was about 0.5 SDs. Our ROC 
decision statistics yielded the strongest discrimination for ASD vs. POP (AUCs = 0.95, 
0.94). Very similar results were reported in previous studies when Italian and Korean 
children with ASD were compared with typically developing children on the DSM-PDP and 
Withdrawn scales (AUCs of 0.93–0.95) (Rescorla 1988; Rescorla et al. 2015; Sikora et al. 
2008; Muratori et al. 2011; Narzisi et al. 2013; Myers et al. 2014).
A unique aspect of our study is that the DD group was subdivided into 646 children without 
ASD features and 284 children with ASD features. Mean scores on the DSM-PDP scale 
were significantly higher for the DD-AF than the DD-noAF group, indicating they were 
phenotypically quite different from each other. Discrimination was also much better for the 
ASD vs. DD-noAF comparison than for the ASD vs. DD-AF comparison (AUCs of 0.90 vs. 
0.71). It is difficult to discern the degree to which the children with developmental delay in 
previous CBCL/1½−5 studies had some ASD features. However, the AUCs of 0.68–0.73 
reported for the Korean sample (Rescorla et al. 2015) as well as AUCs of 0.74–0.75 reported 
for a US sample (Havdahl et al. 2016) suggest that these DD groups were more like our DD-
AF group than our DD-noAF group. A clinical implication of our findings for the DD-AF 
vs. DD-noAF groups is that the DSM-PDP will have fewer false positives if the children 
without an ASD diagnosis also have few ASD features.
In our study, a T score ≥ 65 on DSM-PDP identified 80% of the children in the ASD group 
regardless of the comparison group. However, as hypothesized, SPEC, PPV, and NPV varied 
with the comparison group, with the best results for the ASD-POP comparison (0.93, 0.91, 
0.86). Our decision statistics results are consistent with those reported in the Italian sample 
(Muratori et al. 2011; Narzisi et al. 2013) using a T score ≥ 65 on the DSM-PDP scale to 
compare the ASD and typically developing (TD) groups (SENS = 0.85, SPEC = 0.90, PPV = 
0.88, and NPV = 0.92). Our SENS, SPEC, PPV, and NPV were also comparable to those for 
the Korean sample (Rescorla et al. 2015) using the T ≥ 65 on the DSM-PDP (0.80, 0.87, 
0.55, 0.96), although their PPV was lower because the ASD group was rather small 
compared to the TD group (46 vs. 228).
Using a T ≥ 65 on the DSM-PDP, our SENS, SPEC, PPV, and NPV decision statistics were 
also very good for our ASD-DD-noAF comparison (0.80, 0.85, 0.85, 0.81) and stronger than 
the DD group results for the Korean sample (Rescorla et al. 2015) with respect to SPEC 
(0.60) and PPV (0.36). Compared to results reported by Myers et al. (2014) (SENS = 0.79, 
SPEC = 0.48) and Sikora et al. (2008) (SENS = 0.80, SPEC = 0.42), our DD-noAF SENS 
was comparable but our SPEC was much higher. Our decision statistics for the DD-noAF 
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group were also stronger than those Havdahl et al. (2016) reported for the CBCL Withdrawn 
syndrome with a comparison group of children with developmental and behavioral/
emotional problems (SENS = 0.63, SPEC = 0.65 for a cutpoint ≥ 65). Our results for the 
DD-AF comparison were very similar to those of Myers et al. and Sikora et al. (SENS = 
0.80, SPEC = 0.50); our SENS was higher but SPEC was lower than those reported by 
Havdahl et al. The consistently lower SPEC in the DD-AF group is consistent with previous 
research showing high false positive rates when other behavioral or developmental 
challenges exist (Moody et al. 2017) This highlights the need to develop screeners that 
accurately detect ASD from other developmental challenges.
Consistent with Muratori et al. (2011) and Rescorla et al. (2015), our results were quite 
similar for the DSM-PDP scale and the Withdrawn syndrome. This is not surprising given 
that the scales have five overlapping items. However, the DSM-PDP scale includes some 
important ASD-like behaviors not included among the Withdrawn items (i.e., 63. Repeatedly 
rocks head or body, 80. Strange behavior) and does not include behaviors less specific to 
ASD that are included in the Withdrawn syndrome (i.e., 1. Acts young for age; 62. Refuses 
to play active games). Furthermore, in our study, the DSM-PDP scale had better SENS than 
the Withdrawn syndrome (0.80 vs. 0.66), with only slightly lower SPEC for the typically 
developing group (0.93 vs. 0.96), which is the comparison group most important for Level 1 
screening. Additionally, using the criterion of either DSM-PDP or Withdrawn T ≥ 65 barely 
changed the decision statistics results from those obtained using the criterion of only DSM-
PDP T ≥ 65. Furthermore, 97% of the children with ASD who met the “either” criterion met 
the DSM-PDP criterion, but only 80% of them met the Withdrawn criterion. For all these 
reasons, our results suggest that the DSM-PDP scale is a better screening tool for ASD than 
the Withdrawn syndrome.
Our ROC analyses indicated that the “optimal cutpoint” varied somewhat by scale and by 
comparison group. Furthermore, variable cutpoints are not practical for use by clinical 
practitioners (e.g., pediatricians, nurse practitioners, psychologists, psychiatrists) who are 
screening individual children for ASD risk. Fortunately, a cutpoint of T ≥ 65 yielded strong 
SENS, especially for the DSM-PDP scale, regardless of the comparison group. It also has 
the advantage of demarcating the borderline + clinical ranges (≥ 93rd percentile) on the 
CBCL/1½−5’s DSM-oriented and syndrome scales and is the cutpoint commonly used in 
previous CBCL/1½−5 ASD screening studies.
Our study had numerous strengths. SEED is a multisite case–control study in six states. Our 
sample was very large (N = 2413), with an ASD group of 656 children. An additional 
strength is that we subdivided our DD group into those with no ASD features (n = 646) and 
those with some ASD symptoms but not enough to meet study criteria for ASD (n = 284). 
We had a large population based comparison group (POP) (n = 827). However, limitations of 
our study must also be acknowledged. These include that all groups were not recruited and 
assessed in the same fashion and that some SEED participants (36%) were excluded because 
they lacked CBCL data or a definitive diagnostic classification. Also, children in the DD-AF 
group tended to come from low socioeconomic status, and the ASD sample was composed 
of mostly boys. An additional limitation is that we do not have specific information about 
diagnoses other than ASD or DD for our sample, but Wiggins et al. (2015a) reported some 
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information about diagnoses for the full SEED sample (including those children without 
CBCL/1½−5 scores, whom we excluded for our study). For example, Wiggins found that 
53% of parents/caregivers reported that their child had at least one diagnosis other than 
ASD. Diagnoses of language delay, sensory integration disorder, and motor delay were most 
common in the ASD group. Children classified in the DD-AF group tended to have an 
ADHD diagnosis, whereas those in the DD-noAF group tended to have a Down syndrome 
diagnosis. As would be expected, children in the POP group had the fewest parent-reported 
diagnoses.
Conclusions
Although current AAP guidelines recommend use of an autism-specific screening tool at the 
9-, 18- and 24-month visits for all children, our results suggest that a broad-spectrum 
instrument such as the CBCL/1½−5 might also have several advantages as an ASD screener, 
particularly after the age of 30 months. First, the M-CHAT’s age range is 18 to 30 months, 
whereas the CBCL/1½−5 is normed for children up to age 6, thereby encompassing the age 
range in which ASD may be typically diagnosed. Second, the 99-item CBCL/1½−5 (which 
can be completed by parents in < 15 min either on paper or online) provides normed scores 
on 15 distinct scales and thus screens for a wide range of preschool behavioral/emotional 
problems. Third, the CBCL/1½−5 does not require health professionals to administer or 
score and quickly produces scored output that can be incorporated into an electronic medical 
record. Fourth, since the CBCL is a broad-spectrum instrument tapping many kinds of 
problems, a parent’s pre-existing beliefs about if her/his child has ASD may be less likely to 
influence ratings than a scale with only ASD features. These advantages plus the strong 
screening results found for the CBCL/1½-in the current study and in previous studies 
(Rescorla 1988, 2015; Sikora et al. 2008; Muratori et al. 2011; Narzisi et al. 2013; Myers et 
al. 2014) suggest that the CBCL/1½-,5 has strong potential for use as an ASD screener in 
pediatric settings, particularly in children > 30 months of age, when the use of the M-CHAT 
may no longer be appropriate. Future research comparing results for the CBCL/1½−5 with 
autism-specific screeners in children > 30 months, would be useful in exploring this 
potential.
Despite these many advantages, there are also some drawbacks to using the CBCL/1½−5 in 
pediatric settings. Because the forms are not in the public domain, there is a cost, albeit 
modest, for purchasing/printing each form. Additionally, there is a cost for either the web-
based per-unit scoring utility or for the PC-based unlimited use scoring program. 
Furthermore, entering and scoring each form takes about 5 min for a clerical worker; 
however, if parents complete the form online, scoring is even faster. The scoring results can 
be stored in electronic medical records (EMRs), but some system set up may be required 
initially to ensure compatibility, given the many platforms used for EMRs.
The current results provide evidence for the DSM-oriented PDP scale’s potential as an ASD 
screener to identify children with ASD features who need further evaluation. Because of our 
unique study sample, this evidence is an important advance relative to previous small-scale 
studies. If the CBCL/1½−5 suggests that a child is at risk, a parallel form can be completed 
and scored online by teachers/caregivers, providing valuable multi-informant assessment 
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information not easily obtained using other instruments. We therefore conclude that the 
CBCL/1½−5 is a promising mechanism to identify young children at risk for ASD and other 
problems who can be referred for more detailed assessment.
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Fig. 1. 
Participant selection flow diagram
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